|Bid||87.20 x 800|
|Ask||92.00 x 900|
|Day's Range||87.29 - 89.42|
|52 Week Range||75.81 - 100.03|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 31, 2018 - Aug 6, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||111.70|
Celgene toppled to a four-year low Thursday after it appeared on a list from the FDA attempting to "shame" drugmakers working to block generic competition.
Opening another front in President Donald Trump's war on drug prices, the FDA releases a list of companies "gaming" the system to delay lower-priced generics from getting to market.
SAN RAFAEL, Calif., May 17, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (BMRN) today announced that the company will present data in one platform presentation and three poster presentations at the World Federation of Hemophilia (WFH) 2018 World Congress from May 20-24 in Glasgow, Scotland. The platform presentation will highlight results from the ongoing Phase 1/2 study of its investigational gene therapy, valoctocogene roxaparvovec, for people with severe hemophilia A. The data set evaluates the long-term efficacy and safety of both the 6e13 vg/kg and 4e13 vg/kg doses of valoctocogene roxaparvovec. "As a leader in gene therapy, we appreciate the opportunity to share important emerging data in this scientific forum. We are committed to studying gene therapy, which has the potential to revolutionize care for people with severe hemophilia A," said Hank Fuchs, M.D., President, Worldwide Research and Development at BioMarin.
BioMarin (BMRN) initiates a mid-stage study to evaluate its gene therapy candidate, valoctocogene roxaparvovec for treating in AAV5+ severe hemophilia A.
Merck KGaA (MKGAF) reports dismal first-quarter results with earnings declining year over year. Revenues fall due to continued negative currency movement.
"Administration of valoctocogene roxaparvovec to this first patient seropositive for the AAV5 capsid is an important next step in our plan to expand the number and types of severe hemophilia A patients who may benefit from gene therapy and have antibodies to the vector," said Hank Fuchs, M.D., President, Worldwide Research and Development at BioMarin. The study is an open-label, single-arm, titer-escalation trial evaluating the safety and efficacy of valoctocogene roxaparvovec in AAV5+ hemophilia A patients.
Prices have traded sideways to lower since. In this daily bar chart of BMRN, below, we can see that prices have rallied in the past few weeks to climb above the now rising 50-day moving average line and the still declining 200-day line. The daily On-Balance-Volume (OBV) line has moved up and down with the price action and only in the past two months or so it has diverged from the price action.
NEW YORK, NY / ACCESSWIRE / May 11, 2018 / U.S. markets eked out gains on Thursday, on the back of positive economic data and strong performance from the technology sector. The technology sector has gained ...
NEW YORK, May 11, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Harley-Davidson, ...
"Mad Money" host Jim Cramer thinks lack of trust in the oil futures could hold the key to this market. Cramer also sits down with the CEOs of Groupon and BioMarin. As oil prices hovered in the $70s on Thursday after a recent spike, CNBC's Jim Cramer recalled their 2008 breakdown in a teaching moment for investors.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
This Wednesday morning, WallStEquities.com looks at the performance of these four Biotechnology stocks: AveXis Inc. (NASDAQ: AVXS), Biogen Inc. (NASDAQ: BIIB), Biohaven Pharmaceutical Holding Co. Ltd, (NYSE: BHVN) and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN): All you have to do is sign up today for this free limited time offer by clicking the link below. On Tuesday, shares in Bannockburn, Illinois headquartered AveXis Inc. recorded a trading volume of 941,320 shares, which was above their three months average volume of 884.73 thousand shares. The Company's shares have gained 88.91% over the previous three months and 181.89% in the past twelve months.
BioMarin, Spark and UniQure are duking it out for share in hemophilia gene therapies — a market that could generate north of $1.5 million per patient.
New gene therapies that aim to cure hemophilia, a disease affecting the blood's ability to clot, are on the horizon. Treating hemophilia is costly. In the paradoxical world of drug pricing, the first U.S. price tag exceeding $1 million for a medicine is being contemplated as the nation's agita over the cost of prescription drugs climbs ever higher.
- Bank of America Merrill Lynch Health Care Conference on May 15 in Las Vegas SAN RAFAEL, Calif. , May 2, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Jean-Jacques ...
SAN RAFAEL, Calif., May 1, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (BMRN) announced today that it has been ranked 51st overall among 500 companies on Forbes magazine's 2018 list of "America's Best Mid-size Employers," and third among companies in the biotechnology industry. For more than 20 years, BioMarin has been focused on making a big difference for small patient populations by rapidly developing first-in-class or best-in-class therapies to treat rare genetic diseases. "Forbes seeks to discover which companies operating in the U.S. today are best at making their employees feel happy, inspired, and well-compensated," Forbes explained in presenting a list of 500 mid-size employers selected from about 2,000 companies.
In 1Q18, BioMarin Pharmaceutical’s (BMRN) phenylketonuria drug Kuvan generated revenues of $99.1 million, which reflected ~8% growth on year-over-year (or YoY) basis and an 8% decline quarter-over-quarter. In December 2017, the FDA (Food and Drug Administration) notified BioMarin Pharmaceutical that it will require additional time to review BioMarin’s biologics license application for pegvaliase, a PEGylated recombinant phenylalanine ammonia lyase enzyme for the reduction of phenylalanine levels in blood in adults with phenylketonuria. ...
In February 2018, Vertex Pharmaceuticals (VRTX) announced the results of a Phase 2 trial for VX-150, an investigational NaV1.8 inhibitor. It had positive results in patients with acute pain after bunion removal and was well tolerated by patients.
In 1Q18, Vertex Pharmaceuticals’ (VRTX) revenue rose ~33% YoY (year-over-year) to $638 million from $481 million. It grew ~3% quarter-over-quarter.
In 1Q18, Alexion Pharmaceuticals (ALXN) generated revenues of $930.9 million compared to $870 million in 1Q17, a ~7% increase on a year-over-year (or YoY) basis and a ~2% increase on a quarter-over-quarter basis. In the US, Europe, and Asia-Pacific, Alexion Pharmaceuticals generated revenues of $437.1 million, $270.7 million, and $92.2 million, respectively, compared to $360.1 million, $248.3 million, and $83.0 million in 1Q17.
LONDON, UK / ACCESSWIRE / April 27, 2018 / Active-Investors.com has just released a free research report on Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) ("Concert"). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=CNCE as the Company's latest news hit the wire. On April 25, 2018, the Company announced that it has completed patient enrollment of its Phase-2a trial assessing CTP-543 for the treatment of moderate-to-severe alopecia areata, an autoimmune disorder in which the immune system attacks hair follicles, resulting in patchy or complete hair loss.
Jim Cramer hears from BioMarin Chairman and CEO Jean-Jacques Bienaimé, who discusses new products in his company's pipeline.